City Therapeutics
Cambridge, US · 4 known investors
City Therapeutics develops RNAi-based medicines targeting rare, specialty, and prevalent diseases using engineered trigger molecules and precision delivery ligands. The company aims to expand RNAi therapeutics beyond liver targeting to additional cell and tissue types.
Founders & leadership
MK
Mark Keating, MDCo-founder
KN
Kotaro Nakanishi, PhDCo-founder
YT
Yukihide Tomari, PhDCo-founder
PZ
Phillip Zamore, PhDCo-founder
Investors · 4
In the news
- City Therapeutics Raises $99.5M in Series B Fundingfinsmes.com · 2026
- City Therapeutics builds RNAi pipeline with $99.5M series B - BioSpacebiospace.com · 2026
- City Therapeutics brings in $99.5M Series B to push RNAi programs into clinic - Boston Business Journalbizjournals.com · 2026
- City aims to lay foundation for RNAi renaissance with nearly $100M series Bfiercebiotech.com · 2026
- City Therapeutics gets $99M to gather data on three RNAi medicinesendpoints.news · 2026
- City Therapeutics Launches with $135 Million Series A Financing to Lead the Future of RNAi-based Medicine — City Therapeuticscitytx.com · 2024